SAMN03290910
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.500
- APICAL_SURFACE+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- ANGIOGENESIS+0.300
- APICAL_JUNCTION+0.300
- HEDGEHOG_SIGNALING+0.300
- MYOGENESIS+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- COMPLEMENT+0.200
Top 10 suppressed
- G2M_CHECKPOINT-0.400
- PROTEIN_SECRETION-0.400
- ANDROGEN_RESPONSE-0.300
- E2F_TARGETS-0.300
- MITOTIC_SPINDLE-0.300
- MTORC1_SIGNALING-0.300
- MYC_TARGETS_V1-0.300
- INTERFERON_GAMMA_RESPONSE-0.200
- PI3K_AKT_MTOR_SIGNALING-0.200
- SPERMATOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290888 | — | — | 0.918 |
| 2 | bb3dc2ff-a686-483e-8d3c-e06649462881 | — | — | 0.863 |
| 3 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.862 |
| 4 | c0054cf0-8f4b-47b6-a8fc-63a1fd36bcc7 | — | — | 0.861 |
| 5 | 1652b0a3-dc1d-4490-9632-07673713deb1 | — | — | 0.860 |
| 6 | d496ef4f-4716-4e6e-94e3-fce93b26d4ee | — | — | 0.860 |
| 7 | 399cd50c-1439-48a4-ba3b-a0782b2b7b62 | — | — | 0.849 |
| 8 | 16ab68fd-4948-4cd5-b5d8-1b2e8a1fd3cb | — | — | 0.848 |
| 9 | 57583139-d2d3-4b97-a616-aa96058d4682 | — | — | 0.845 |
| 10 | 44f9e45d-d779-4865-8f10-d085d5d25447 | — | — | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.500 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.400 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |